As prostate cancer screenings based on prostate-specific antigen tests are mainly performed as optional tests in Ningen Dock, whose number recovered to the prepandemic level in 2021 (Figure 1), it is likely that the number of examinees undergoing prostate cancer screenings also recovered in 2021, although the exact number is unknown. The gene discussed is KLK3; the disease is prostate carcinoma.